Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CRISPR Therapeutics

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose

- PMLiVE

Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn

The acquisition will focus on expanding the company’s blood disorders portfolio

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Janssen’s teclistamab granted conditional marketing authorisation by EC

The decision makes teclistamab the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

- PMLiVE

Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn

The acquisition will help accelerate research into sickle cell disease

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval

Breast cancer is the most diagnosed type of cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020

- PMLiVE

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe

- PMLiVE

MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug

Oxybryta is the first treatment in Britain to directly block sickle haemoglobin polymerisation

- PMLiVE

European Commission approves potential new treatment for Pompe disease

Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe in over 15 years

- PMLiVE

Novartis and Precision BioSciences announce in vivo gene editing collaboration

The companies will work together to develop potentially curative treatments for disorders including sickle cell disease and beta thalassaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links